title: A prospective, interventional assessment of the impact of ustekinumab treatment on psoriasis-related work productivity and activity impairment.
abstract: BACKGROUND
  The negative impact of psoriasis on quality of life is well documented. Psoriasis is also associated with impairments in work productivity and daily activities.
  
  
  OBJECTIVE
  This study was conducted to prospectively measure the impact of ustekinumab treatment on work productivity and daily activity impairments due to psoriasis, using the Work Productivity and Activity Index: Psoriasis instrument.
  
  
  METHODS
  Thirty-two patients with moderate-to-severe plaque psoriasis received 36 weeks of ustekinumab and were followed every 4 weeks. During each visit, patients were evaluated using the Psoriasis Area Severity Index and Work Productivity and Activity Index: Psoriasis instrument.
  
  
  RESULTS
  Thirty-two patients completed the study. There was no change in unemployment rate after treatment. Twenty-two patients who were employed at both baseline and week 36 experienced a significant decrease in total work productivity impairment, presenteeism and a non-significant decrease in absenteeism. All patients demonstrated significant reduction in total activity impairment.
  
  
  CONCLUSIONS
  This study was limited by the lack of a placebo group and a small sample size.
  
  
  CONCLUSIONS
  This study demonstrates the benefits of ustekinumab treatment in terms of reducing psoriasis-related work productivity and activity impairments among patients with moderate-to-severe psoriasis.
authors.affiliation: a Department of Dermatology , University of California San Francisco , San Francisco , CA , USA.
authors.forename: Kourosh
authors.initials: K
authors.lastname: Beroukhim
authors.affiliation: a Department of Dermatology , University of California San Francisco , San Francisco , CA , USA.
authors.forename: Melissa
authors.initials: M
authors.lastname: Danesh
authors.affiliation: a Department of Dermatology , University of California San Francisco , San Francisco , CA , USA.
authors.forename: Catherine
authors.initials: C
authors.lastname: Nguyen
authors.affiliation: a Department of Dermatology , University of California San Francisco , San Francisco , CA , USA.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Farahnik
authors.affiliation: a Department of Dermatology , University of California San Francisco , San Francisco , CA , USA.
authors.forename: Ethan
authors.initials: E
authors.lastname: Levin
authors.affiliation: a Department of Dermatology , University of California San Francisco , San Francisco , CA , USA.
authors.forename: Argentina
authors.initials: A
authors.lastname: Leon
authors.affiliation: a Department of Dermatology , University of California San Francisco , San Francisco , CA , USA.
authors.forename: John
authors.initials: J
authors.lastname: Koo
mesh_terms: D000041:Absenteeism; D000203:Activities of Daily Living; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004526:Efficiency / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome; D000069549:Ustekinumab / Q000627:therapeutic use*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D000069549:Ustekinumab
keywords: biologic therapy; cost savings; patient-reported outcomes; treatment outcomes